Patient-Derived Xenograft Organoids (PDXOs) are advanced 3D in vitro models developed from tumors expanded in mouse models and then cultured to preserve cancer stem cells and tumor complexity. These models closely reflect the histological, genomic, and phenotypic features of the original patient tumors, making them ideal for predictive drug screening. At Apricell, we utilize PDXO technology to offer physiologically relevant, scalable platforms that bridge the gap between preclinical testing and clinical outcomes. Our models help researchers and biotech partners accelerate cancer therapy development with confidence and precision.